Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 124 participants.
Also called NCT05114590
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 124 participants
- Sponsor
- Registry
-
NCT05114590 -
U1111-1261-7399
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT05114590. Allocation not applicable; no masking; primary purpose treatment. Start 2022-01-27 (actual); primary completion 2023-03-28 (actual). Results posted on 2024-05-24.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus
- Acronym
- Soli-CGM
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Insulin glargine/Lixisenatide
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct05114590- Content hash
4584c4410ee10e67a9f1c21a93217b43da2cdde595946ac878ef503e4d083bf6